Deutsche Bank AG grew its position in Teligent (NASDAQ:TLGT) by 82.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 90,938 shares of the company’s stock after acquiring an additional 41,119 shares during the period. Deutsche Bank AG owned 0.17% of Teligent worth $329,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of TLGT. Broadfin Capital LLC raised its stake in shares of Teligent by 35.1% in the fourth quarter. Broadfin Capital LLC now owns 1,925,415 shares of the company’s stock valued at $6,989,000 after acquiring an additional 500,000 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in Teligent by 282.7% in the 4th quarter. UBS Asset Management Americas Inc. now owns 51,034 shares of the company’s stock worth $185,000 after purchasing an additional 37,700 shares during the last quarter. Wells Fargo & Company MN raised its position in Teligent by 52.4% in the 3rd quarter. Wells Fargo & Company MN now owns 49,264 shares of the company’s stock worth $331,000 after purchasing an additional 16,937 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its position in Teligent by 26.1% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 74,300 shares of the company’s stock worth $270,000 after purchasing an additional 15,400 shares during the last quarter. Institutional investors own 65.38% of the company’s stock.
Teligent opened at $2.87 on Friday, Marketbeat reports. The company has a debt-to-equity ratio of 3.07, a current ratio of 2.73 and a quick ratio of 2.01. Teligent has a fifty-two week low of $2.43 and a fifty-two week high of $9.54. The company has a market capitalization of $153.58 million, a P/E ratio of -15.11 and a beta of 0.73.
Teligent (NASDAQ:TLGT) last posted its quarterly earnings data on Tuesday, May 8th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Teligent had a negative return on equity of 27.25% and a negative net margin of 28.98%. The company had revenue of $14.55 million during the quarter, compared to the consensus estimate of $15.62 million. sell-side analysts forecast that Teligent will post -0.04 EPS for the current fiscal year.
Several research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Teligent from a “hold” rating to a “sell” rating in a research report on Thursday, May 10th. Canaccord Genuity set a $4.00 price objective on shares of Teligent and gave the stock a “hold” rating in a research report on Wednesday, May 9th. Finally, ValuEngine upgraded shares of Teligent from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. Teligent currently has a consensus rating of “Hold” and an average price target of $7.00.
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.